case_images: PMC10033877_01
case_images: Histopathology and immunohistochemistry (IHC) of the biopsies from liver metastases. (A) Histological findings revealed squamous cell carcinoma (HE x 200). (B) IHC staining for the expression of programmed cell death-ligand 1 (x200). (C, D) IHC staining yielded positive results for CK20 (C) and P40 (D) (x200).
case_images: fonc-13-1051786-g001.jpg
case_images: PMC10033877_01_fonc-13-1051786-g001.jpg
case_images: f1
case_images: The biopsy of the hepatic lesions revealed metastatic SCC (Figure 1A). The PD-L1 CPS was 20 (Figure 1B). The immunohistochemical staining of the biopsy specimen revealed a positive expression of CK20 (Figure 1C), P40 (Figure 1D), P63, CK20, CK5/6, MLH1, MSH2, MSH6, and PMS2.
case_images: Computed tomography portal phase images. Maximum diameter of the liver (A-C) and lung (D-F) metastases. (A) 28.7 mm, before the combination therapy. (B) 18.46 mm, after two cycles of combination therapy. (C) 6.39 mm, after eight cycles of combination therapy. (D) Before combination therapy. (E) After two cycles of combination therapy. (F) After eight cycles of combination therapy.
case_images: fonc-13-1051786-g002.jpg
case_images: PMC10033877_01_fonc-13-1051786-g002.jpg
case_images: f2
case_images: After two cycles of combination therapy, CT showed that the liver lesion had shrunk from 28.7 to 18.46 mm (Figures 2A, B); hence, the patient had achieved a partial response. The liver lesion had shrunk to 6.39 mm after eight cycles of the combination therapy (Figure 2C). Significant tumor shrinkage was also observed in the lung lesion (Figures 2D-F).